Inflammatory Bowel Diseases clinical trials

Explore recruiting inflammatory bowel diseases clinical trials.

Recruiting inflammatory bowel diseases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Inflammatory Bowel Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Investigating the safety, feasibility, and optimal dose of fluorescently labeled Adalimumab-680LT for visualizing drug targeting in Inflammatory Bowel Diseases.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

MOVE-IT: MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independant Randomized Controlled Trial

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A study to evaluate how well single and multiple doses of O3R-5671-PRO are tolerated in healthy adult subjects

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function (VERDA)

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

I6T-MC-AMAZ: A master protocol for a Phase 3, multicenter, open-label, long-term extension study to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease

Poland, Italy, Austria, Belgium, France, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Inflammatory Bowel Diseases trials by city

Inflammatory Bowel Diseases in Toronto Inflammatory Bowel Diseases in Vancouver Inflammatory Bowel Diseases in Montreal Inflammatory Bowel Diseases in Calgary Inflammatory Bowel Diseases in Edmonton Inflammatory Bowel Diseases in Ottawa Inflammatory Bowel Diseases in Winnipeg Inflammatory Bowel Diseases in Quebec City Inflammatory Bowel Diseases in Hamilton Inflammatory Bowel Diseases in Kitchener Inflammatory Bowel Diseases in London Inflammatory Bowel Diseases in Halifax Inflammatory Bowel Diseases in New York Inflammatory Bowel Diseases in Los Angeles Inflammatory Bowel Diseases in Chicago Inflammatory Bowel Diseases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease